arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xenetic Biosciences, Inc.

XBIO
$1.90 ▼ -0.12 (-6.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xenetic Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.4M
Dividend Yield —
Revenue Growth 12.0% ↘
Op. Margin -147.1% ↘
ROIC -12.6% ↘
FCF / Share $-0.38 ↘
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$660.60K
↑ +12.0% —
Net Income Profit after all expenses
$-929.70K
↓ -35.0% —
Operating Margin Operating profit as % of sales
-147.1%
↓ -136.4% 2th
FCF / Share Free cash flow per share
$-0.38
↓ -63.0% —
Long-Term Debt Long-term obligations
$212.81K
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↓
20
Cash Quality →
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 62 quarters